nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

4. Kollagenosen

verfasst von : Rudolf Puchner, Judith Sautner

Erschienen in: Rheumatologie aus der Praxis

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zu den Kollagenosen gehören: der systemische Lupus erythematodes (SLE), die Mischkollagenose (Mixed Connective Tissue Disease – MCTD, Sharp-Syndrom), die systemische Sklerose, das Sjögren-Syndrom und die systemischen Myositiden. Der Beitrag umfasst die Beschreibung der wichtigsten Krankheiten unter Berücksichtigung neuer Klassifikationskriterien und neuer Erkenntnisse in der Behandlung. Mehrere Fallbeispiele tragen zum Verständnis diagnostischer Schritte und komplexer Therapieentscheidungen bei.

Vorheriges Kapitel Spondyloarthritiden

Nächstes Kapitel Familiäres Mittelmeerfieber

[1]

Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48 [Suppl 3]:iii 3–7 (Review)

[2]

Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575CrossRefPubMed

[3]

Andreoli L, Bertsias GK, Agmon-Levin N et al. (2016) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis Jul 25. Epub ahead of print. doi: 10.1136/annrheumdis-2016-209770

[4]

Aringer M, Hiepe S (2011) Systemischer Lupus erythematodes. Z Rheumatol 70:313–323CrossRefPubMed

[5]

Aringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31:411–442CrossRefPubMed

[6]

Bertsias GK, Ionnidis JPA, Boletis J et al. (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 67:195–205CrossRefPubMed

[7]

Bertsias GK, Ioannidis JP, Aringer M et al. (2010) EULAR recommendations for the management of systemic lupus erythematosis with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082CrossRefPubMed

[8]

Blank N, Max R, Lorenz HM (2006) The role of DMARDs in systemic sclerosis therapy. Rheumatology 45 [Suppl 3]:iii 2–4

[9]

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed

[10]

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRefPubMed

[11]

Brito-Zeron P, Theander E, Baldini C et al. (2016) Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12(2): 137–156CrossRefPubMed

[12]

Cervera R, Khamashta MA, Font J et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308CrossRef

[13]

Cipriani P, Di Benedetto P, Ruscitti P et al. (2015) Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther 17:247CrossRefPubMedPubMedCentral

[14]

Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 49:585–593CrossRefPubMed

[15]

Distler JHW (2008) Primäres und sekundäres Raynaud Phänomen. Z Rheumatol 67:211–219CrossRefPubMed

[16]

Dörner T (2008) Sjögren-Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 817–824CrossRef

[17]

Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Meyer J et al. (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban & Fischer, München

[18]

Feist E, Dörner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren-Syndrom. Z Rheumatol 66:679–685CrossRefPubMed

[19]

Fischer-Betz R, Schneider M (2008) Lupus erythematodes-evidenzbasierte Empfehlungen zu Überwachung und Therapie. Z Rheumatol 67:491–499CrossRef

[20]

Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331CrossRefPubMed

[21]

Fries JF, Hochberg MC, Medsger TA et al. and ACR Diagnostic and Therapeutic Criteria Committee (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37:454–462CrossRefPubMed

[22]

Fries R, Shariat K, Wilmowsky H von, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed

[23]

Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRefPubMed

[24]

Genth E (2008) Systemische Sklerose. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 801–816CrossRef

[25]

Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228CrossRefPubMed

[26]

Gladman D, Ginzler E, Goldsmith C et al. (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMed

[27]

Gromnica-Ihle E (2008) Mixed connective tissue disease (Sharp-Syndrom). In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 824–830

[28]

Hochberg MC (1997) Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed

[29]

Hoeper M (2003) Pulmonale arterielle Hypertonie. In: Hoeper M (Hrsg) Endothelin-Rezeptor-Antagonismus als neues Therapieprinzip bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, S 30–53

[30]

Hoogen van den F, Khanna D, Fransen J et al. (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747CrossRef

[31]

Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993CrossRefPubMed

[32]

LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 15:202–205PubMed

[33]

Masi AT, Rodnan GP, Medsger T et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef

[34]

Matucci-Cerinic M, Krieg T, Guillevin L et al. (2016) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75(19):1770–1776CrossRefPubMed

[35]

Meijer J, Meiners P, Vissink A et al. (2010) Effective rituximab treatment in primary Sjögren’s syndrome: A randomised, double-blind, placebo controlled trial. Arthritis Rheum 62:960–980CrossRefPubMed

[36]

Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73:490–494CrossRefPubMed

[37]

Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMed

[38]

Navarra SV, Guzman RM, Gallacher AE et al. (2011) Efficacy and safety of belimumab in patients with systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial. Lancet 377:721–731CrossRefPubMed

[39]

Pavlov-Dolijanovic S, Damanov NS, Vujasinovic Stupar NZ et al. (2013) The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud’s phenomenon. Rheumatol Int 33(12):2967–2973CrossRefPubMed

[40]

Petri M, Orbai AM, Alarcon GS et al. (2012) Derivation and validation of the Sytemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedPubMedCentral

[41]

Richter J (2015) Idiopathische Myositiden - Dermatomyositis und Polymyositis. In: Hettenkofer HJ, Schneider M, Braun J (Hrsg) Rheumatologie, 6. Aufl. Thieme, Stuttgart, S 251–262

[42]

Richter J, Iking-Konert C (2007) Aktuelle Therapien der Dermatomyositis und Polymyositis. Z Rheumatol 66:686–682CrossRefPubMed

[43]

Riemekasten G, Dragun D (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Z Rheumatol 66:672–678CrossRefPubMed

[44]

Riemekasten G, Schulze-Koops H (2005) Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z Rheumatol 64:123–136CrossRefPubMed

[45]

Rösler KM, Scheidegger O (2015) Myositiden. Z Rheumatol 74:496–506CrossRefPubMed

[46]

Ryden-Aulin M, Boumpas D, Bultink I et al. (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 6;3(1): e000163CrossRef

[47]

Saar P, Müller-Ladner U (2006) Die systemische Sklerose – Eine rheumatologische Herausforderung. Z Rheumatol 65:429–440CrossRefPubMed

[48]

Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kaskawa R, Sharp GC (Hrsg) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, S 23–32

[49]

Sharp GC, Irvin WS, Tan EM et al. (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159CrossRefPubMed

[50]

Shiboski SC, Shiboski CH, Criswell L et al. (2012) New Classification Criteria for Sjögren’s Syndrome: A data-driven expert – clinician consensus approach within the SICCA Cohort. Arthritis Care Res 64:475–487CrossRef

[51]

Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol [Suppl II]: 1–151

[52]

Specker C (2016) Antiphospholipidsyndrom Z Rheumatol 75:570–574

[53]

Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed

[54]

Tashkin DP, Elashoff R, Clements PJ et al., Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666CrossRefPubMed

[55]

Vitali C, Bombardieri S, Jonsson R et al. (2002) European Study Group on Classification Criteria for Sjogren’s Syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the America-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentral

[56]

Witte T (2014) Sjögren-Syndrom. Z Rheumatol 73:49–61CrossRefPubMed

[57]

Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165:2337–2344CrossRefPubMed

[58]

Zuber M, Koch B, Gause A, Pfreundschuh M (1996) Diagnose und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wschr 121:913–918CrossRefPubMed

Titel: Kollagenosen
verfasst von: Rudolf Puchner
Judith Sautner
Verlag: Springer Berlin Heidelberg
Buch: Rheumatologie aus der Praxis
Print ISBN: 978-3-662-53568-4

Electronic ISBN: 978-3-662-53569-1

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-53569-1_4

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten